Topiramate for treating alcohol dependence: a randomized controlled trial

Area of Science:

• Neuroscience
• Pharmacology
• Addiction Medicine

Background:

• Alcohol dependence is a significant public health issue.
• Topiramate's mechanism involves modulating neurotransmitter systems implicated in addiction.
• Previous research suggests potential benefits of topiramate for alcohol use disorder.

Purpose of the Study:

• To evaluate the safety and efficacy of topiramate in treating alcohol dependence.
• To determine if topiramate can reduce alcohol consumption and heavy drinking days.

Main Methods:

• A 14-week, double-blind, randomized, placebo-controlled trial involving 371 adults with alcohol dependence.
• Participants received up to 300 mg/day of topiramate or placebo, with weekly compliance enhancement.
• Primary outcome was self-reported percentage of heavy drinking days; secondary outcomes included other drinking measures and plasma gamma-glutamyltransferase levels.

Main Results:

• Topiramate significantly reduced the percentage of heavy drinking days compared to placebo (mean difference, 8.44% to 16.19%; P < .002).
• All secondary drinking outcomes also showed significant improvement with topiramate (P < .001).
• Common adverse events with topiramate included paresthesia, taste perversion, anorexia, and concentration difficulties.

Conclusions:

• Topiramate is a safe and efficacious treatment for alcohol dependence.
• The findings support topiramate as a promising therapeutic option for individuals struggling with alcohol use disorder.